Roquefort Therapeutics plc Share Price
Equities
ROQ
GB00BMDQ2T15
Investment Management & Fund Operators
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.54 GBX | -0.22% | -4.42% | -37.38% |
26/04 | EARNINGS AND TRADING: Aura confident in Tiris; Cindrigo enters Germany | AN |
26/04 | Earnings Flash (ROQ.L) ROQUEFORT THERAPEUTICS Reports FY23 Loss GBX-1.35 | MT |
Sales 2021 | 637 798.25 66.63K | Sales 2022 | - | Capitalization | 8.56M 10.72M 895M |
---|---|---|---|---|---|
Net income 2021 | - 0 0 | Net income 2022 | -1M -1.25M -105M | EV / Sales 2021 | 10,439 x |
Net cash position 2021 | 900K 1.13M 94.11M | Net cash position 2022 | 2.32M 2.91M 243M | EV / Sales 2022 | - |
P/E ratio 2021 |
-3.77
x | P/E ratio 2022 |
-4.24
x | Employees | 9 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 29.02% |
1 day | -0.22% | ||
1 week | -4.42% | ||
Current month | -35.14% | ||
1 month | -35.14% | ||
3 months | -32.74% | ||
6 months | -33.96% | ||
Current year | -37.38% |
Managers | Title | Age | Since |
---|---|---|---|
Ajan Reginald
CEO | Chief Executive Officer | 52 | 16/22/16 |
Chairman | 51 | 17/20/17 | |
Armand Keating
CTO | Chief Tech/Sci/R&D Officer | - | 16/22/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jean Duvall
BRD | Director/Board Member | 63 | 05/22/05 |
Darrin Disley
BRD | Director/Board Member | 57 | 16/22/16 |
Chairman | 51 | 17/20/17 |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 4.54 | -0.22% | 63 506 |
26/24/26 | 4.55 | 0.00% | 421,949 |
25/24/25 | 4.55 | -4.21% | 725,100 |
24/24/24 | 4.75 | 0.00% | 500,000 |
23/24/23 | 4.75 | 0.00% | 1,373 |
Delayed Quote London S.E., April 29, 2024 at 03:30 pm IST
More quotes1st Jan change | Capi. | |
---|---|---|
-37.38% | 7.32M | |
-6.03% | 113B | |
-3.75% | 87.91B | |
+20.42% | 63.85B | |
+5.29% | 61.9B | |
+10.12% | 42.86B | |
+7.95% | 40.84B | |
+19.21% | 34.58B | |
+5.88% | 25.46B | |
-5.25% | 22.13B |
- Stock Market
- Equities
- ROQ Stock